Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Stage I of phase III Neutralase study completed

June 14, 1999

Roberts' Agrylin receives orphan drug status in Japan

June 10, 1999

Elevated troponin T levels predict beneficial response to abciximab in unstable angina

June 8, 1999

Potent, orally active antiplatelet fibrinogen antagonists in early development at Ortho-McNeil

June 8, 1999

Chiron begins first clinical trial of in vivo gene therapy for hemophilia

June 4, 1999

PGI2 agonists under study at Fujisawa

June 2, 1999

Orally active anticoagulants described by Daiichi

June 2, 1999

New perspectives for rFVIIa and rFVIIai

June 1, 1999

Fragmin approved in U.S. for treatment of unstable angina and non-Q wave MI

May 31, 1999

Avigen cleared to begin human trials of gene therapy product for hemophilia

May 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...